Citation & Authors
Osteoarthritis Cartilage. 2026;34(8):1270–1280.
ABSTRACT · RESEARCH SUMMARY
Research summary
This new-user, active-comparator study matched 59,157 pairs of denosumab and bisphosphonate users. Denosumab was associated with a lower risk of knee osteoarthritis (HR 0.87; 95% CI 0.84–0.91), with no significant differences for hip or thumb carpometacarpal osteoarthritis. This is an observational association following treatment selection; clinical trials are needed to establish whether knee OA can be prevented.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
After matching, each group included 59,157 patients. Compared with bisphosphonates, denosumab was associated with a lower risk of incident knee osteoarthritis (HR 0.87; 95% CI 0.84–0.91), but hip osteoarthritis did not differ significantly (HR 0.98; 95% CI 0.94–1.03).
Findings differed between the knee and hip. This observational study does not establish that denosumab prevents or treats osteoarthritis; confirmation in clinical trials is needed.
